t began 70 years ago as a simple concept: inhibin described a gonadal principal that suppresses production and release of pituitary follicle-stimulating hormone.' The picture became complicated when, during efforts to purify inhibin, fractions were isolated that were shown to stimulate folliclestimulating hormone release from pituitary tissues.1 Further purification steps led to the identity of activin as a homodimer of inhibin's beta subunits. 2 Shortly thereafter, receptors for activin were identified. Later, in another side fraction of inhibin, follistatin was purified, cloned, and then shown to bind irreversibly to and neutralize activin.1'3 Because these proteins are produced and released together in a variety of tissues, increasing attention has been directed to their actions as autocrine and paracrine growth factors, rather than endocrine regulators. The most recent thinking is that activin signaling is regulated extracellularly by its antagonism to inhibin and by its binding to follistatin. Its intracellular response is further modulated by intracellular regulatory proteins. It is believed that a balance between activin and its principal modulators, inhibin and follistatin, determine considerably activin's final biologic effect.14 In this issue, two studies that examined the role of activin and its modulators on two important issues in reproduction are published: one study addresses endometrial maturation and implantation and the other, premature labor.
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In a report by Florio et a15 from the University of Siena, the authors examined activin A and follistatin mRNA (by reverse transcriptase-polymerase chain reaction) and peptide expression (by immunocytochemistry) in both glandular and stromal endometrial cellular elements. They also examined secretion of these proteins into the endometrial cavity by measuring activin A and follistatin concentrations (by enzyme-linked immunosorbent assay) in washings obtained by endometrial lavage. They compared the measurements obtained in the follicular and luteal phases. The results show that activin A, but not follistatin peptide expression and secretion, is increased in the secretory phase of the menstrual cycle. These findings suggest that a mechanism exists by which the biologic activity of activin A is increased at the time of implantation by its heightened availability through differential suppression of follistatin release. Because there is an abundance of activin receptors in maternal endometrium and preimplantation embryonic tissues, this process regulating availability and biologic activity of activin may be an important element in the messaging between fetal and matemal tissues that guide timing and location of implantation. 4 Considerable progress has been made in the study of the activin-inhibin-follistatin system during the past 5 years. Other studies examining interactions of this system are providing new insight into the pathophysiology of poor responders in assisted reproductive technology, polycystic ovarian disease, and ovarian neoplasia. Several of these articles have appeared recently and others are subjects of future reports.
